Gabapentin
Product Images NDC 68071-3464

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-3464). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3464 3)

Gabapentin 100mg capsules by NuCare Pharmaceuticals, Inc. The label indicates a package size of 30 capsules. Each oblong white opaque capsule contains 100mg of Gabapentin, USP, with 'YT 44' printed in black ink on the body. The label includes the NDC number 68071-3464-3 and cautions to keep out of reach of children and store at controlled temperature 68-77°F.*

FDA Label Image

Image Description (Gabapentincapsules 01)

An illustration showing the formula for calculating creatinine clearance (CLCr), with variables including age (years), weight (kg), serum creatinine (mg/dL), and a multiplier for female patients (0.85).*

FDA Label Image

Chemical Structure (Gabapentincapsules 02)

Chemical structure of Gabapentin showing a cyclohexane ring bonded to aminomethyl and acetic acid functional groups.*

FDA Label Image

Figure 1 (Gabapentincapsules 03)

A line graph depicting mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, noting a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin showing a decline in pain score over time compared to stable scores for placebo.*

FDA Label Image

Figure 2 (Gabapentincapsules 04)

Line graph showing mean pain score over a 7-week period for placebo and two gabapentin doses (1800 mg/day and 2400 mg/day). The graph tracks changes starting from baseline through a 3-week dose titration period and a 4-week fixed dose period, indicating pain score trends over time by treatment group.*

FDA Label Image

Figure 3 (Gabapentincapsules 05)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different dosages in two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600, while Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 and 2400 respectively, with significance indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentincapsules 06)

A scatter plot graph showing the difference percentage on the vertical axis against daily dose in milligrams (mg) on the horizontal axis. It compares results from three studies labeled as Study a, Study b, and Study c, with data points ranging from 600 mg to 1800 mg daily dose and difference values approximately between 7% to 17%. Study a uses black squares, Study b gray squares, and Study c white squares as markers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.